All In Biotech

Drug Trial Radar · NCT03536884

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 743 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

743

Actual

Start

Jun 13, 2018

Primary completion

Sep 12, 2019

Study completion Aug 9, 2023

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
May 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).

Conditions

  • Chronic Plaque Psoriasis
  • Moderate to Severe Chronic Plaque Psoriasis

Interventions

  • BimekizumabDrug

    Subjects will receive bimekizumab at pre-specified time-points.

  • SecukinumabDrug

    Subjects will receive secukinumab at pre-specified time-points.

  • PlaceboOther

    Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16Time frame: Week 16

Locations

77 sites in 11 countries. Site status is shown where the registry gives one.

  • Ps0015 975

    Santa Ana, California

  • Ps0015 939

    Danbury, Connecticut

  • Ps0015 903

    Ocala, Florida

  • Ps0015 921

    Ormond Beach, Florida

  • Ps0015 977

    Pembroke Pines, Florida

  • Ps0015 936

    Tampa, Florida

  • Ps0015 976

    Tampa, Florida

  • Ps0015 970

    West Palm Beach, Florida

  • Ps0015 966

    Sandy Springs, Georgia

  • Ps0015 954

    Skokie, Illinois

  • Ps0015 972

    West Dundee, Illinois

  • Ps0015 900

    West Des Moines, Iowa

  • Ps0015 944

    New Orleans, Louisiana

  • Ps0015 915

    Clayton, Missouri

  • Ps0015 953

    St Louis, Missouri

  • Ps0015 901

    Portsmouth, New Hampshire

  • Ps0015 965

    Kew Gardens, New York

  • Ps0015 969

    High Point, North Carolina

  • Ps0015 971

    Wilmington, North Carolina

  • Ps0015 980

    Bexley, Ohio

  • Ps0015 920

    Portland, Oregon

  • Ps0015 929

    Portland, Oregon

  • Ps0015 979

    Dallas, Texas

  • Ps0015 924

    Houston, Texas

  • Ps0015 978

    Pflugerville, Texas

  • PS0015 3

    Carlton, Australia

  • PS0015 7

    Hectorville, Australia

  • PS0015 6

    Kogarah, Australia

  • Ps0015 11

    Parkville, Australia

  • PS0015 9

    Woolloongabba, Australia

  • Ps0015 50

    Brussels, Belgium

  • Ps0015 54

    Brussels, Belgium

  • Ps0015 52

    Liège, Belgium

  • Ps0015 673

    Halifax, Canada

  • Ps0015 671

    Hamilton, Canada

  • Ps0015 663

    Mississauga, Canada

  • Ps0015 661

    Peterborough, Canada

  • Ps0015 678

    Richmond Hill, Canada

  • Ps0015 677

    Toronto, Canada

  • Ps0015 657

    Waterloo, Canada

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.